Table 1 Liquid biopsy analytes and potential utility as diagnostic biomarkers
From: Potential clinical utility of liquid biopsies in ovarian cancer
Analyte | Author, Year | Tumour Subtype and Staging | Number of patients | Laboratory Technique | Detection Rate | Ref |
|---|---|---|---|---|---|---|
CTCs | Zhang et al., 2018 | Stage I-IV EOC | 109 | Immunomagnetic bead screening, Multiplex RT-PCR | 90% | [181] |
Guo et al., 2018 | Stage I-IV EOC | 30 | Microfluidic isolation and immunofluorescent staining | 73% | [182] | |
Pearl et al., 2014 | Stage I-IV EOC | 129 | CAM-based identification platform | Sensitivity = 83% PPV = 97.3% | [184] | |
Poveda et al., 2011 | Stage I-IV EOC | 216 | CellSearch system and reagents (Veridex) | 14.4% had 2 or more CTCs prior to therapy | [183] | |
Pearl et al., 2015 | Stage I-IV EOC | 123 | iCTC flow cytometry assay | Sensitivity = 83% Specificity = 97% | [185] | |
ctDNA | Wang et al., 2017 | Stage I-IV EOC | 194 | QIAamp DNA blood mini kit, promoter methylation OPCML, TFPI2 and RUNX3 | Sensitivity = 90.14 Specificity = 91.87 | [154] |
Dong et al., 2012 | Stage I-IV EOC | 36 | Methylation-specific PCR | 80.6% | [158] | |
Wu et al., 2014 | Stage I-IV EOC | 47 | Methylation-specific PCR | 51.1% | [156] | |
Bondurant et al., 2011 | Stage I-IV EOC | 106 | Methylation-specific PCR | 51% | [159] | |
Liggett et al., 2011 | Stage III-IV EOC | 30 | Microarray-mediated methylation assay | Sensitivity = 90.0% Specificity = 86.7% | [160] | |
Widschwendter et al., 2017 | Stage I-IV EOC | 43 | Reduced representation bisulfite sequencing | Sensitivity = 23% Specificity = 97% | [161] | |
Forshew et al., 2012 | Stage III-IV EOC | 46 | Targeted deep sequencing | Sensitivity = 97.5% Specificity = 97.5% | [162] | |
Du et al., 2018 | Stage II-III EOC | 21 | High-throughput sequencing | Sensitivity = 73.7% Specificity = 100% | [165] | |
Vanderstichele et al., 2017 | Stage I-IV EOC | 57 | Whole-genome sequencing | Sensitivity = 2- to fivefold higher than CA-125 Specificity = 99.6% | [166] | |
Cohen et al., 2016 | Stage I-IV EOC | 32 | DNA sequencing and whole genome NIPT | Sensitivity = 40.6% Specificity = 93.8%, | [167] | |
Wang et al., 2015 | Stage I-IV EOC | 114 | Multiplex nested methylated specific PCR | Sensitivity = 90.14% Specificity = 91.06% | [155] | |
Zhang et al., 2013 | Stage I-IV EOC | 87 | Methylation-specific PCR | Sensitivity = 89.66% Specificity = 90.57% | [157] | |
Dvorská et al., 2019 | Stage I-IV EOC | 49 | Pyrosequencing | Sensitivity = 98% Specificity = 56% | [171] | |
Su et al., 2009 | Stage I-IV EOC | 26 | Methylation-specific PCR | Sensitivity = 73% Specificity = 75% | [172] | |
Melnikov et al., 2009 | Stage I-IV EOC | 33 | Microarray mediated methylation assay | Sensitivity = 85% Specificity = 61% | [175] | |
Singh et al., 2020 | Stage I-IV EOC | 70 | TaqMan based qPCR assay | Sensitivity = 89% Specificity = 100% | [176] | |
Cohen et al., 2018 | Stage I-III EOC | 54 | Combined assays for genetic alterations and protein biomarkers (CancerSEEK) | Sensitivity = 98% Specificity = 99% | [177] | |
Exosomes | Schwich et al., 2019 | Stage I-IV EOC | 78 | Nanoparticle tracking analysis, ELISA | 100% | [187] |